Additionally, targeting of B7-H3, Mac-1 and Endoglin (mAb25, mAb26, and mAb27) has been reported to polarize TAMs from their common, pro-tumorigenic (“M2”) state towards an anti-tumorigenic (“M1”) state, potentially enhancing anti-tumor immune responses36–38. The gene discussed is CD276; the disease is neoplasm.